Skip to main content
MYGN
NASDAQ Life Sciences

Myriad Genetics CEO Buys Nearly $200K in Stock Following Recent Financial Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.83
Mkt Cap
$449.774M
52W Low
$3.76
52W High
$11.44
52W Position info
28% above low
Off High info
58% below high
Rel. Volume info
2.8× avg
Market data snapshot near publication time

MYGN sits 28% above its 52-week low of $3.76 on elevated volume (2.8× avg).

Summary

Myriad Genetics' President and CEO, Samraat S. Raha, purchased $199,844 worth of common stock in an open market transaction, signaling executive confidence after recent financial challenges.


Key Events · Ownership and Investor Activity · MYGN

  • CEO Stock Purchase

    President and CEO Samraat S. Raha acquired 40,000 shares of common stock for a total of $199,844 at an average price of $5.00 per share, which is slightly above the current market price of $4.83.

  • Vote of Confidence Amidst Challenges

    This purchase by a key executive follows the company's recent disclosure of a $365.9 million net loss and the filing of a $200 million universal shelf registration, suggesting executive belief in the company's prospects despite recent challenges.


Analysis · MYGN · Life Sciences

This open market purchase by President and CEO Samraat S. Raha signals a vote of confidence in Myriad Genetics, especially coming after the company reported a significant net loss and filed a universal shelf registration due to losing its 'well-known seasoned issuer' status. The CEO's decision to invest nearly $200,000 in company stock at an average price of $5.00 per share, slightly above the current market price of $4.83, suggests a belief in future recovery or undervaluation, potentially counteracting recent negative sentiment.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MYGN was trading at $4.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $449.8M. The 52-week trading range was $3.76 to $11.44. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MYGN - Latest Insights

MYGN
Nov 05, 2026, 9:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.71
Real-time Price: $6.82 info
Change: +$0.112 (+2%) info
Market Cap: $575.811M info
MYGN
Nov 04, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.72
Real-time Price: $6.82 info
Change: +$0.102 (+2%) info
Market Cap: $575.811M info
MYGN
Nov 04, 2026, 4:06 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $6.60
Real-time Price: $6.82 info
Change: +$0.222 (+3%) info
Market Cap: $575.811M info
MYGN
Oct 20, 2026, 9:27 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $5.47
Real-time Price: $6.82 info
Change: +$1.36 (+25%) info
Market Cap: $575.811M info
MYGN
Oct 20, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.61
Real-time Price: $6.82 info
Change: +$2.21 (+48%) info
Market Cap: $575.811M info